Business Operations (Details Narrative) - USD ($) |
3 Months Ended | 6 Months Ended | 30 Months Ended | ||
|---|---|---|---|---|---|
Jun. 30, 2015 |
Jun. 30, 2014 |
Jun. 30, 2015 |
Jun. 30, 2014 |
Jun. 30, 2015 |
|
| Organization And Business Operations [Line Items] | |||||
| Original estimated cost of clinical trial lab | $ 2,038,000 | ||||
| Cost of clinical trial lab | 150,107 | $ 93,581 | $ 500,708 | $ 173,233 | $ 1,202,536 |
| Cash and money market funds | $ 1,250,579 | 1,250,579 | $ 1,250,579 | ||
| Proceeds from sale of Series A Convertible Preferred Stock | 1,750,000 | ||||
| Proceeds from exercise of warrants | 315,000 | $ 1,412,500 | |||
| September 30, 2016 [Member] | |||||
| Organization And Business Operations [Line Items] | |||||
| Current estimated cost of clinical trial lab | $ 2,615,000 | ||||
| X | ||||||||||
- Definition Carrying value of cash and money market funds. No definition available.
|
| X | ||||||||||
- Definition The cost incurred for clinical trial lab. No definition available.
|
| X | ||||||||||
- Definition Current estimated cost of clinical trial lab. No definition available.
|
| X | ||||||||||
- Definition Organization And Business Operations Line Items. No definition available.
|
| X | ||||||||||
- Definition Original estimated cost of clinical trial lab. No definition available.
|
| X | ||||||||||
- Definition The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash inflow associated with the amount received from holders exercising their stock warrants. No definition available.
|
| X | ||||||||||
- Details
|